Firm pushes innovation as pharma growth driver

n n

Laboratory solutions provider LS Scientific has said innovation and access to advanced laboratory technologies remain critical to the growth of Nigeria’s pharmaceutical sector amid rising regulatory expectations and infrastructure gaps.

n

The company stated this during its participation at the Pharma West Africa 2026 held in April in Lagos, where regulators, manufacturers and solution providers gathered to discuss challenges affecting the industry and pathways for sustainable growth.

n

In a statement, the firm explained that Nigeria’s pharmaceutical market, estimated at over $2bn, has continued to expand on the back of growing demand for locally manufactured medicines. But it noted that weak quality control infrastructure, limited access to modern laboratory systems and stricter regulatory standards have continued to limit the sector’s competitiveness globally.

n

Speaking at the exhibition, the Managing Director of LS Scientific, Murewa Odunjo, said the event had become an important platform for driving pharmaceutical development across Africa.

n

“Pharma West Africa represents more than an exhibition; it’s a catalyst for the next phase of pharmaceutical growth on the continent,” said Odunjo.

n

“We are glad to contribute to its growth by showcasing a range of advanced solutions for the sector,” Odunjo added.

n

At the exhibition, LS Scientific showcased laboratory technologies from international partners, including ERWEKA Germany, IKA Germany, Metrohm Switzerland, Astell UK, VELP Italy, Chemlab Belgium, Wasserlab Spain, Phenomenex USA, DWK UK, ELGA UK, Scharlab Spain and VWR UK.

n

Participants said the exhibition reflected increasing demand for innovation within the pharmaceutical industry, especially as firms seek to improve compliance, efficiency and product quality.

n

“The diversity of laboratory equipment here reflects where the industry needs to go,” said an attendee, who added that modern laboratory systems would play a major role in strengthening compliance and consistency across pharmaceutical operations.

n

Odunjo also disclosed that the company had introduced a financing scheme aimed at easing the burden of capital investment for pharmaceutical firms, noting that the initiative will allow companies to acquire major laboratory equipment, instruments, chemicals and consumables at discounted rates with a six-payment plan.

n

Industry stakeholders at the exhibition stressed that the future growth of Nigeria’s pharmaceutical sector would depend on sustained investment in infrastructure, wider access to technology and stronger collaboration among operators across the value chain.

n n